Biohaven Ltd.
18.11+0.91 (+5.29%)
Oct 29, 4:00:02 PM EDT · NYSE · BHVN · USD
Key Stats
Market Cap
1.92BP/E (TTM)
-Basic EPS (TTM)
-7.46Dividend Yield
0%Recent Filings
8-K
FDA skips advisory for troriluzole
Biohaven Ltd. received FDA notification on August 21, 2025, that no advisory committee meeting is required for its troriluzole NDA targeting Spinocerebellar Ataxia in adults. This follows a three-month PDUFA extension from May 2025 to review recent submissions. The decision streamlines the process. FDA approval remains on track for Q4 2025.
8-K
Biohaven amends Knopp deal
Biohaven Ltd. filed a prospectus supplement on August 15, 2025, enabling resale of 3,588,688 common shares issued to a selling shareholder under the May 1, 2024 Knopp Amendment. This amendment swapped scaled high single-digit to low-teens royalties for mid-single-digit flat royalties on BHV-7000 and pipeline programs, while slashing success milestones from up to $1,137.5 million to $270 million, with $25 million already paid. The deal streamlines payments, favoring cash or shares at Biohaven's option. Yet risks linger if approvals falter.
10-Q
Q2 FY2025 results
Biohaven narrowed its Q2 operating loss to $211.7M from $333.8M a year earlier, thanks to R&D spend dropping to $184.4M from $314.8M as clinical programs like troriluzole and Kv7 modulators advance without major new hits. Net loss improved to $198.1M or $1.94 per diluted share on 102.4M shares, versus $319.8M or $3.64 last year, while YTD figures show $419.8M loss or $4.11 per share against $499.3M prior. Cash burn eased with operating cash use at $333.1M YTD, offset by $250M in new senior secured notes tied to future troriluzole sales; quarter-end cash and equivalents hit $165.8M, plus $239.2M in marketable securities. Recent Merus ADC pact and Highlightll amendment expand oncology and neuroinflammation pipelines. Yet regulatory hurdles for unproven therapies loom large.
8-K
Biohaven Q2 results and pipeline
Biohaven reported Q2 2025 financials on August 11, showing a net loss of $198.1 million, down from $319.8 million last year, thanks to no repeat of a big one-time expense, while R&D costs hit $184.4 million amid pipeline pushes. Cash reserves stand at $408.2 million, funding key advances like VYGLXIA's SCA NDA nearing FDA decision in Q4 2025 and degraders BHV-1300 and BHV-1400 slashing IgG and Gd-IgA1 by up to 87% and 81%. Pipeline momentum builds. Yet regulatory approval remains uncertain.
8-K
Biohaven's degrader breakthroughs
Biohaven unveiled its June 2025 investor presentation, spotlighting Phase 1 successes for novel MoDE and TRAP degraders that selectively slash disease-causing proteins like Gd-IgA1 by up to 81% in IgA nephropathy and IgG by 83% in autoimmune targets, paving the way for pivotal trials in Graves' disease by late 2025 and IgAN by early 2026. BHV-7000's Kv7 activator nears pivotal readouts for depression in second-half 2025 and epilepsy in 2026, while troriluzole's NDA for spinocerebellar ataxia advances under priority review toward a PDUFA in late 2025. Degraders promise precision without broad immunosuppression, yet trial risks linger.
ABVC
ABVC Biopharma, Inc.
2.77-0.13
BIIB
Biogen Inc.
147.86-1.27
BIVI
BioVie Inc.
1.80-0.06
BMRN
BioMarin Pharmaceutical Inc.
51.86-1.63
BTAI
BioXcel Therapeutics, Inc.
2.07-0.11
DRUG
Bright Minds Biosciences Inc.
53.94-3.52
IMVT
Immunovant, Inc.
21.65-0.33
TVGN
Tevogen Bio Holdings Inc.
0.62+0.01
ZBIO
Zenas BioPharma, Inc.
28.01-2.18
ZURA
Zura Bio Limited
3.78+0.01